An immune-protein score combining TRAIL, IP-10 and CRP for predicting severe COVID-19 disease
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.06.27.21259196: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Study approval: Ethical approval was obtained from each medical center with informed consent covered by the original protocol. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:An inherent limitation of this study is its retrospective design allowing only routinely measured data parameters to be evaluated. As a …
SciScore for 10.1101/2021.06.27.21259196: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: Study approval: Ethical approval was obtained from each medical center with informed consent covered by the original protocol. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:An inherent limitation of this study is its retrospective design allowing only routinely measured data parameters to be evaluated. As a result, signature performance could not be compared to other commonly used severity scores or biomarkers and certain data points were not available (e.g., time from symptom onset) or missing. Also, the study period did not encompass multiple genetic variants of SARS-CoV-2. These limitations should be addressed in future independent signature validation studies. The signature was derived based on a population treated under protocols applied in the first and second waves of the pandemic, and its performance has not yet been evaluated in populations treated with newer approaches. Future studies are required to validate the performance of this novel severity signature and to establish its utility in the evolving workflow of COVID-19 patient management, specifically in supporting decisions on escalation and de-escalation of care. A notable benefit of this immune-based tool, as compared to severity scores already in use, is that it predicts immune dysregulation associated with lung damage (25–27). Furthermore, unlike other severity scores, the three constituent proteins and signature can be easily and rapidly measured at the point-of-need using one platform. In summary, the derived signature together with the rapid measurement platform have potential to serve as a practical predictive tool for early indication of COVID-19 patients at-risk for sever...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
